<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03741257</url>
  </required_header>
  <id_info>
    <org_study_id>N-55-2018</org_study_id>
    <nct_id>NCT03741257</nct_id>
  </id_info>
  <brief_title>Comparison Between Two Concentration of Hypertonic Saline in Intestinal Obstruction Surgery</brief_title>
  <official_title>Hypertonic Saline 3% Compared to Hypertonic Saline 1.8% for Fluid Management of Intestinal Obstruction Surgery</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Cairo University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Cairo University</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Background and Rationale :&#xD;
&#xD;
      Perioperative fluid management is a challenging issue in surgical care especially in a&#xD;
      procedure specific model. Recently hypertonic saline (HS) has the advantage of using the&#xD;
      patient's own total body water by drawing interstitial space. Although it still controversial&#xD;
      whether HS is associated with benefits in specific patient populations, particularly with&#xD;
      respect to site of lesion and illness severity; these data provide insight into therapeutic&#xD;
      modalities to curtail ileus formation.&#xD;
&#xD;
      Objectives :&#xD;
&#xD;
        -  Measurement of total volume of fluid infused, the need of inotropic or vasopressor to&#xD;
           maintain adequate hemodynamic parameters with assessment of electrolyte disturbances and&#xD;
           S.lactate&#xD;
&#xD;
        -  The incidence rate of surgical complications; infection and anastomotic dehiscence&#xD;
&#xD;
      Study population &amp; Sample size :&#xD;
&#xD;
      There were no previous trials comparing the two studied groups of the current trial. We&#xD;
      expected a small standardized effect size of 0.2. Based on this effect size, 25 subjects will&#xD;
      be needed to elicit the difference between the two groups at an alpha level of 0.05 and power&#xD;
      of 0.9 (Whitehead et al; 2016).&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Recruiting</last_known_status>
  <start_date type="Actual">November 1, 2018</start_date>
  <completion_date type="Anticipated">February 2020</completion_date>
  <primary_completion_date type="Anticipated">November 2019</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Supportive Care</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Total volume of infused fluids</measure>
    <time_frame>24 hours</time_frame>
    <description>the total volume of fluids given to subjects intraoperatively and postoperatively</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>surgical complications rate</measure>
    <time_frame>4 days</time_frame>
    <description>the rate of surgical complications i.e leakage and wound dehisence</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">50</enrollment>
  <condition>Intestinal Obstruction Fluid Management With Hypertonic Saline</condition>
  <arm_group>
    <arm_group_label>Group A</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Received Hypertonic saline 3% as resuscitation fluid.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Group B</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Received Hypertonic saline 1.8% as resuscitation</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Hypertonic saline</intervention_name>
    <description>resuscitation fluid</description>
    <arm_group_label>Group A</arm_group_label>
    <arm_group_label>Group B</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Age: 20-70 years old&#xD;
&#xD;
          -  ASA≤III&#xD;
&#xD;
          -  BMI 25-40kg/m.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Severe CVS diseases (EF&lt;50%)&#xD;
&#xD;
          -  Severe pulmonary diseases (Pulmonary function test ≤ 50% of predicted)&#xD;
&#xD;
          -  Neurological disorders; Psychological diseases, demyelinating lesions, Parkinsonism,&#xD;
             motor or sensory disorders.&#xD;
&#xD;
          -  Pregnancy.&#xD;
&#xD;
          -  Severe chronic renal disease (s. Creatinine&gt; 2gm/dl or patients on dialysis).&#xD;
&#xD;
          -  Severe hepatic impairment (Child &amp; Pugh classification class C).&#xD;
&#xD;
          -  Acid-base and electrolytes disturbances.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>20 Years</minimum_age>
    <maximum_age>70 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Rasha Behery, MD</last_name>
    <phone>+201228604556</phone>
    <email>rasha.behery.rz@gmail.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Ahmed Lotfy, MD</last_name>
    <phone>+201000608905</phone>
    <email>ahmed.lotfy@kasralainy.edu.eg</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Cairo University Hospitals</name>
      <address>
        <city>Cairo</city>
        <zip>11562</zip>
        <country>Egypt</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Ahmed Lotfy, MD</last_name>
      <phone>+201000608905</phone>
      <email>ahmed.lotfy@kasralainy.edu.eg</email>
    </contact>
  </location>
  <location_countries>
    <country>Egypt</country>
  </location_countries>
  <verification_date>November 2018</verification_date>
  <study_first_submitted>November 11, 2018</study_first_submitted>
  <study_first_submitted_qc>November 13, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">November 14, 2018</study_first_posted>
  <last_update_submitted>November 13, 2018</last_update_submitted>
  <last_update_submitted_qc>November 13, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">November 14, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Cairo University</investigator_affiliation>
    <investigator_full_name>Ahmed Mohamed Lotfy</investigator_full_name>
    <investigator_title>lecturer of anesthesia and intensive care</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Intestinal Obstruction</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

